Compare Keysight Technologies Inc (KEYS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Sana Biotechnology Inc — how do they compare? Keysight Technologies Inc trades at $352.97 (market cap $58.74B), while Sana Biotechnology Inc trades at $3.83 (market cap $1.13B). The key difference: Keysight Technologies Inc is far larger — about 52× Sana Biotechnology Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| KEYS | SANA | |
|---|---|---|
Market Cap | $58.74B | $1.13B |
Sector | Technology | Health |
52-Week High | $373.34 | $5.92 |
52-Week Low | $158.51 | $2.68 |
Enterprise Value | $59.08B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $335.41, down 1.63% on the day, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a 17.31% net income margin and consistent earnings beats, with Q1 2026 EPS of $2.87 surpassing the $2.32 estimate. Recent developments include new product launches and strategic collaborations, such as the certification of electromagnetic design software for Intel's latest processes (Business Wire, 2026-07-27).
The outlook for KEYS is positive, driven by earnings growth and innovation in test and measurement solutions. Key opportunities include expansion in 5G and cybersecurity markets, though risks involve high valuation multiples and competitive pressures. The consensus price target of $396.56 implies significant upside potential from current levels.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
